Karyopharm Therapeutics Inc.
For the period ended Sep 30, 2025. Filed Nov 3, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 3, 2025
KPTI$0.02-56.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| For the Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities | ||
| Net loss | $(93,841) | $(45,642) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 10,147 | 14,562 |
| Depreciation and amortization | 277 | 259 |
| Amortization of debt issuance costs and discounts | 8,101 | 4,012 |
| Net amortization of premiums and discounts on investments | (401) | (2,112) |
| Gain on extinguishment of debt | — | (44,702) |
| Change in fair value of embedded derivatives and common stock warrants | (10,596) | (18,343) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (1,111) | (4,816) |
| Inventory | 773 | (1,629) |
| Prepaid expenses and other assets | 4,219 | (2,933) |
| Operating lease right-of-use assets | 1,204 | 1,690 |
| Accounts payable | 285 | 2,660 |
| Accrued expenses and other liabilities | 17,622 | (2,253) |
| Operating lease liabilities | (220) | (2,429) |
| Net cash used in operating activities | (63,541) | (101,676) |
| Investing activities | ||
| Proceeds from maturities of investments | 38,378 | 138,187 |
| Purchases of investments | — | (57,316) |
| Purchases of property and equipment | — | (195) |
| Net cash provided by investing activities | 38,378 | 80,676 |
| Financing activities | ||
| Proceeds from issuance of senior secured term loan | — | 83,300 |
| Proceeds from the exercise of stock options and shares issued under the employee stock purchase plan | 356 | 772 |
| Payment of debt issuance costs | — | (2,588) |
| Payment of deferred royalty obligation | — | (40,518) |
| Net cash provided by financing activities | 356 | 40,966 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | 15 | 9 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (24,792) | 19,975 |
| Cash, cash equivalents and restricted cash at beginning of period | 62,814 | 53,192 |
| Cash, cash equivalents and restricted cash at end of period | $38,022 | $73,167 |
| Reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets | ||
| Cash and cash equivalents | $37,672 | $72,828 |
| Short-term restricted cash | — | 33 |
| Long-term restricted cash | 350 | 306 |
| Total cash, cash equivalents and restricted cash | $38,022 | $73,167 |
| Supplemental disclosures: | ||
| Cash paid for interest on deferred royalty obligation | $3,711 | $18,926 |
| Cash paid for interest on convertible debt and term loan | $10,668 | $11,472 |
| Cash paid for amounts included in the measurement of operating lease liabilities | $1,023 | $2,844 |
| Convertible senior notes due 2029 issued with warrants to purchase 3,100 shares of common stock in exchange for a $148,000 reduction of convertible senior notes due 2025 | $— | $111,000 |
| Senior secured term loan issued in exchange for a $14,700 reduction of deferred royalty obligation | $— | $15,000 |
| Issuance of common stock used to settle a financial advisory fee related to financing activities | $— | $7,697 |
| Convertible senior notes due 2029 issued in exchange for a $5,000 reduction of deferred royalty obligation | $— | $5,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.